Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10059685HBVENSG00000158125.10protein_codingXDHNoNo7498P47989
TVIS10059683HBVENSG00000158125.10protein_codingXDHNoNo7498P47989
TVIS10059682HBVENSG00000158125.10protein_codingXDHNoNo7498P47989
TVIS10059684HBVENSG00000158125.10protein_codingXDHNoNo7498P47989
TVIS30050045HIVENSG00000158125.10protein_codingXDHNoNo7498P47989
TVIS20014252HPVENSG00000158125.10protein_codingXDHNoNo7498P47989
TVIS20066584HPVENSG00000158125.10protein_codingXDHNoNo7498P47989
TCGA Plot Options
Drug Information
GeneXDH
DrugBank IDDB04854
Drug NameFebuxostat
Target IDBE0002204
UniProt IDP47989
Regulation Typeinhibitor
PubMed IDs23286293; 25501928; 16958189; 19337428
CitationsSaban-Ruiz J, Alonso-Pacho A, Fabregate-Fuente M, de la Puerta Gonzalez-Quevedo C: Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):94-9.@@Nishino T, Okamoto K: Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout. J Biol Inorg Chem. 2015 Mar;20(2):195-207. doi: 10.1007/s00775-014-1210-x. Epub 2014 Dec 12.@@Pohar S, Murphy G: Febuxostat for prevention of gout attacks. Issues Emerg Health Technol. 2006 Aug;(87):1-4.@@Hu M, Tomlinson B: Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1209-20. doi: 10.2147/tcrm.s3310.
GroupsApproved
Direct ClassificationThiazolecarboxylic acids and derivatives
SMILESCC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
Pathways
PharmGKBPA165958521
ChEMBLCHEMBL1164729